Akero Therapeutics, Inc. (AKRO)
US — Healthcare Sector
Automate Your Wheel Strategy on AKRO
With Tiblio's Option Bot, you can configure your own wheel strategy including AKRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AKRO
- Rev/Share 0.0
- Book/Share 12.5526
- PB 3.5331
- Debt/Equity 0.0363
- CurrentRatio 12.6587
- ROIC -0.3023
- MktCap 3547512150.0
- FreeCF/Share -3.1011
- PFCF -13.9983
- PE -12.7636
- Debt/Assets 0.0335
- DivYield 0
- ROE -0.3157
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AKRO | H.C. Wainwright | -- | Buy | -- | $72 | Sept. 4, 2025 |
| Initiation | AKRO | TD Cowen | -- | Buy | -- | $76 | Aug. 4, 2025 |
| Upgrade | AKRO | BofA Securities | Neutral | Buy | $35 | $63 | Jan. 30, 2025 |
| Reiterated | AKRO | H.C. Wainwright | -- | Buy | $50 | $72 | Jan. 27, 2025 |
News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation
AKRO
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
About Akero Therapeutics, Inc. (AKRO)
- IPO Date 2019-06-20
- Website https://www.akerotx.com
- Industry Biotechnology
- CEO Andrew Cheng
- Employees 69
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.